Dipali Patel oversees all aspects of CMC development at Epicrispr ranging from tech transfer to supply chain management. Prior to joining Epicrispr, Dr. Patel held roles of increasing responsibility at SanBio, Inc. in quality control, process, and analytical development for the generation of validated release assays, including potency, and a new automated closed system manufacturing platform for allogeneic mesenchymal stem cell therapy. She played a crucial role in the successful J-BLA filing of SanBio’s lead product, SB623, in Japan. Previously Dr. Patel worked in analytical development at Aduro Biotech where she drove CMC development of their personalized attenuated L. mono vaccine. Dr. Patel received her B.Sc. and Ph.D. in biomedical engineering from the University of California, Davis.